Physician profile
Sharon E Leonard
NPI 1760519367
$8,010.21
in general payments reported to CMS, 2019-2025
21 companies · $4,688 in 2025
The $4,688 reported for 2025 was more than what 80% of Pediatric Allergy/Immunology providers received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $62.78 · 2021: $163 · 2022: $261 · 2023: $309 · 2024: $2,138 · 2025: $4,688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,588 · Food and Beverage: $2,518 · Travel and Lodging: $27.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,588.00 |
| Food and Beverage | $2,518.16 |
| Travel and Lodging | $27.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $4,473.40 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $1,169.79 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $440.72 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $281.24 | 2019-2025 | Fasenra, Tezspire |
| Biocryst US Sales Co., LLC | $270.46 | 2021-2025 | Orladeyo |
| Csl Behring | $178.05 | 2019-2025 | Andembry, Haegarda |
| Alk-Abello, INC | $164.74 | 2019-2025 | Grastek, Odactra, Ragwitek |
| Lilly USA, LLC | $154.50 | 2024 | Ebglyss, Taltz |
| Greer Laboratories, INC. | $151.49 | 2025 | Palforzia, Oralair |
| Aimmune Therapeutics, INC. | $108.29 | 2022 | |
| Pfizer INC. | $107.17 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.82 | 2023-2025 | Cuvitru |
| Genentech USA, INC. | $86.22 | 2024-2025 | Xolair |
| Glaxosmithkline, LLC. | $73.95 | 2023-2024 | Nucala |
| Kaleo, INC. | $56.80 | 2022-2024 | Auvi-Q |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $53.38 | 2023-2024 | Xembify |
| Nestle Healthcare Nutrition INC. | $48.14 | 2023 | |
| Ars Pharmaceuticals Operations, INC. | $46.22 | 2025 | Neffy |
| Lnhc, INC | $21.44 | 2025 | Zelsuvmi |
| Arcutis Biotherapeutics, INC. | $20.95 | 2025 | Zoryve |
| Circassia INC. | $15.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Leonard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.